Orchard Therapeutics logo

Orchard Therapeutics

Orchard Therapeutics is a clinical-stage biotechnology company developing ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in primary immune deficiencies, metabolic diseases and haematological disorders.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”ORTX” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.orchard-tx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENASDAQ: ORTX
Address
Birchin Court20, Birchin Lane EC3V 9DU
London
United Kingdom
Email
Contact Number
+44 203 384 6700

Orchad Therapeutics is in partnerships with University College London (_UCLÓ), Great Ormond Street Hospital for Children NHS Foundation Trust (_GOSHÓ), the University of Manchester, the University of California Los Angeles (_UCLAÓ) and Boston Childrens Hospital for the development of transformative gene therapies for serious and life-threatening orphan diseases.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/orchard-therapeutics” connections=”true” suffix=””]

In Apr 2018, Orchard and GSK signs strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard. Under the agreement, GSK will become an investor receiving a 19.9% equity stake. Orchard has acquired Strimvelis, for ADA-SCID, MLD, WAS and for three additional preclinical programmes.

In Dec 2017, Orchard complet an oversubscribed $110 million (£85 million) Series B financing. Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.

In Nov 2016, Orchard Therapeutics and UCLA receive $19 million of funding from California Institute for Regenerative Medicines governing board (CIRM).

In May 2016, Orchard Therapeutics raised a £21 Mn in Series A financing led by F-Prime Capital.